What changed: Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

When this page itself was last checked or edited.

CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome

Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy

Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.

A milestone in how this cancer is treated.

Topical treatment of mycosis fungoides-type CTCL (Ledaga)

Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017.

A milestone in how this cancer is treated.

Topical treatment of stage IA and IB mycosis fungoides-type CTCL after skin-directed therapy (Valchlor)

CAILS response 58.

Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL

Cutaneous T-cell lymphoma after ≥1 systemic therapy

Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies

A milestone in how this cancer is treated.

Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment

Cutaneous manifestations of cutaneous T-cell lymphoma refractory to at least one systemic therapy

Palliative treatment of skin manifestations of cutaneous T-cell lymphoma unresponsive to other therapy, by extracorporeal photopheresis

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.

ALL, choriocarcinoma, and later osteosarcoma, breast, head and neck, lung, lymphoma, mycosis fungoides

Hodgkin disease and other lymphomas, leukaemias, mycosis fungoides (intravenous; discontinued)

A milestone in how this cancer is treated.